Category Archives: Stem Cell Treatment


Stem Cell Therapy Market Regulations and Competitive Landscape Outlook – 3rd Watch News

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/217

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

Hospitals Ambulatory Surgical Centers

Stem Cell Therapy Market, By Application:

Oncology Central Nervous System Diseases Eye Diseases Musculoskeletal Diseases Wound & Injuries Metabolic Disorders Cardiovascular Disorders Immune System Disorders

Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/217

Stem Cell Therapy Market, By Geography:

North America Europe Asia Pacific Middle East & Africa Latin America

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are: Gamida Cell ReNeuron Group, plc Osiris Therapeutics, Inc. Stem Cells, Inc. Vericel Corporation. Mesoblast, Ltd.

Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/217

See the original post here:
Stem Cell Therapy Market Regulations and Competitive Landscape Outlook - 3rd Watch News

Global Stem Cell Therapy Market (2019-2029) with COVID-19 After Effects Analysis by Emerging Trends, Industry Demand, Growth, Key Players – 3rd Watch…

The new research report titled Stem Cell Therapy Market published by Global Marketers into his huge database. Primary and secondary research methodologies have been used to formulate this report. This Report Provides an in-depth study analyzing the current and future demands of this market also it provides the overview, definition, cost structure, segmentation, recent developments, application,and industry chain analysis, CAGR growth, and Porters Five Forces Analysis, demand. The report has offered an all-inclusive analysis of the global market taking into consideration all the pivotal aspects like growth factors, market developments, future prospects, and trends.

Get/Download Free sample report, @ https://www.globalmarketers.biz/report/life-sciences/2014-2029-report-on-global-stem-cell-therapy-market-by-player,-region,-type,-application-and-sales-channel/152309 #request_sample

Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCRPharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

This Stem Cell Therapy market report will help you determine and analyze your portfolio of key market players with information such as company profile, components and services offered, financial information from the past three years, and key developments it helps you to develop a strategy to gain a competitive edge in the past 4-5 years.

North America (United States, Canada), Asia-Pacific (China, Japan, India, Australia, and South Korea), Latin America (Brazil, Mexico, etc.), The Middle East and Africa (GCC and South Africa), Europe (Germany, Spain, France, UK, Russia, and Italy)

The competitive landscape of the Stem Cell Therapy Market is discussed in the report, including the market share and new orders market share by the company. The report profiles the leading players in the market for providing an in-depth study of this industry as well as provides growth opportunities, future demands of this market. The report also discusses the implemented by the key vendors to maintain their hold on the industry. The business overview and financial overview of each of the key vendors have been analyzed in this research Report.

The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period. This report defines the current and present situation as well as the future forecast of this Stem Cell Therapy Market. Also, this report provide all the information on Impact Analysis of COVID-19 on this industry.

Stem Cell Therapy Market By Type:

Autologous Allogeneic

Stem Cell Therapy Market By Application:

Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Hurry Up!!! Ask For Discount https://www.globalmarketers.biz/discount_inquiry/discount/152309

For more Information or Browse the complete report @ https://www.globalmarketers.biz/report/life-sciences/2014-2029-report-on-global-stem-cell-therapy-market-by-player,-region,-type,-application-and-sales-channel/152309 #table_of_contents

Read this article:
Global Stem Cell Therapy Market (2019-2029) with COVID-19 After Effects Analysis by Emerging Trends, Industry Demand, Growth, Key Players - 3rd Watch...

Farrah Fawcett Glimpse into Life and Final Days of the Beloved ‘Charlie’s Angels’ Star – AmoMama

Farrah Fawcett became an actress known for her beauty andcompassionate nature. As June 25 marked the 11th anniversary of her passing, we looked at memorable moments in her career - from that swimsuit poster to her role in "Charlie's Angels."

At the age of 62, Farrah Fawcett passed away on June 25, 2009, in Santa Monica, California. While her death came on the same day as Michael Jackson's passing, it brought her battle with cancer to a final close.

Her final days, Fawcett spent worried about her family -her son, Redmond, in particular. Fawcett shared Redmond with Ryan O'Neal with whom she had a complicated relationship, and his bumpy road down the wrong path heightened her protective instinct.

Fawcett's close friend Mela Murphy, who stayed by her side at St. John's Health Center until she died, recalled the actress's final moments to PEOPLE and said:

She was saying his name, Redmond.' That was the last thing she said.I told her Id take care of him, that Ill always be there for him."

The actress died a few hours later after what Jaclyn Smith, Fawcett's co-star in "Charlie's Angels," called a "relentless fight" against anal cancer.

Following her first cancer diagnosis in 2006, Fawcett founded The Farrah Fawcett Foundation in aid of HPV-related cancer research after she got declared cancer-free in February 2007.

But the status was short-lived, asa routine check-up three months later revealed a small malignant polyp. Fawcett went to Germany to undergo experimental stem-cell treatment, but sadly it didn't have the results they hoped on.

However, Fawcett remained steadfast in her battle against the disease, one her partner Ryan O'Neal knew about from first-hand experience.

O'Neal and Fawcett initially separated in 1997 after almost two decades together. But when doctors told O'Neal in 2001 that he had leukemia, they reconciled until she died in 2009.

During her acting career, Fawcett earned 10 award wins and 23 nominations, and it includes her role in "Charlie's Angels." Then there is that unforgettablered swimsuit Fawcett posedin during 1976.It sold12 million copies and becamethebest-selling poster of all time.

The poster launched Farrah Fawcett into stardom since she had only done small roles and television commercials up until that point.

Fawcett had even remained under the radar with roles in series such as "I Dream of Jeannie," "The Flying Nun," and a recurring role in "Harry O" when she decided to accept the poster deal.

Continued here:
Farrah Fawcett Glimpse into Life and Final Days of the Beloved 'Charlie's Angels' Star - AmoMama

COVID-19 Outbreak Bestows Lucrative Opportunities to Rheumatoid Arthritis Stem Cell Therapy Market; Demand to Remain High Post Pandemic – Daily…

Analysis of the Global Rheumatoid Arthritis Stem Cell Therapy Market

A recent market research report on the Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report sheds light on the different segments of the Rheumatoid Arthritis Stem Cell Therapy market and provides a thorough understanding of the growth potential of each market segment over the forecast period (20XX-20XX).

According to the analysts at Fact.MR, the Rheumatoid Arthritis Stem Cell Therapy market is evenly poised to register a CAGR growth of ~XX% during the assessment and surpass a value of ~US$ XX by the end of 2029. The report analyzes the micro and macro-economic factors that are likely to impact the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the upcoming years.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Key Insights Enclosed in the Report

Segmentation of the Rheumatoid Arthritis Stem Cell Therapy Market

The presented report dissects the Rheumatoid Arthritis Stem Cell Therapy market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

COVID-19 Analysis

The report encompasses the major developments within the global Rheumatoid Arthritis Stem Cell Therapy market amidst the novel COVID-19 pandemic. The report offers a thorough understanding of the different aspects of the market that are likely to be feel the impact of the pandemic.

Important doubts related to the Rheumatoid Arthritis Stem Cell Therapy market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

The rest is here:
COVID-19 Outbreak Bestows Lucrative Opportunities to Rheumatoid Arthritis Stem Cell Therapy Market; Demand to Remain High Post Pandemic - Daily...

A Preview of the 12 Propositions on Californias November Ballot – Times of San Diego

These three measures, all placed on the ballot by the Legislature, had been introduced before protests against racism and police brutality swept the country. But as California lawmakers look for ways to play a role in the national debate about institutional barriers to equity and the meaning of citizenship, many legislators see these as particularly potent causes.

Prop. 16: Ending the ban on affirmative action

Who put it there: The Legislature, via abillby San Diego Democrat Assemblymember Shirley Weber

Type: Constitutional amendment

What it would do: Allow schools and public agencies to take race and other immutable characteristics into account when making admission, hiring or contracting decisions.

In 1996 California voters passedProposition 209, a constitutional amendment banning affirmative action at state institutions. The result was an immediate drop in Black and Latino enrollment at the states elite public universities. Some civil rights organizations have been trying to repeal Prop. 209 ever since.

Each of those attempts has been stymied by a coalition of Republicans, moderate Democrats and some progressive legislators who represent districts with large Asian American voting populations. This year, as in previous years, some of the most vocal and persistent opponents of the effort to reintroduce affirmative action have beenChinese-American political activists. They argue that boosting enrollment of students from underrepresented racial groups would come at the expense of overrepresented Asian American students.

Prop. 17: Restoring the right to vote to people on parole

Who put it there: The Legislature, via abillby Sacramento Democrat Assemblymember Kevin McCarty.

Type: Constitutional amendment

What it would do:Allow Californians who are currently on parole to vote.

In 1974, California voters passed a ballot measure giving people who have committed felonies the right to vote once they complete their sentences and are no longer on parole.

Thanks to that law, there are some 40,000 Californians who are not in prison but unable to legally cast a ballot. But as with any criminal justice debate, this is also one about race. According to anestimate from 2016, two thirds of people on parole in the state are Latino or Black.

Prop. 18: Letting (some) 17 year olds vote (some of the time)

Who put it there: The Legislature, with abillintroduced by San Mateo Democrat Assemblymember Kevin Mullin.

Type: Constitutional amendment

What it would do: Allow 17-year-old U.S. citizens to vote in a primary and special election as long as they will turn 18 by the subsequent general election.

California Democrats have been on a decade-long tear increasing voting access. Same-day voter registration, automatic registration at the DMV and pre-registration of 16- and 17-year-olds are among the recent pro-vote innovations to come out of the Capitol.

Letting people under 18 vote would be yet another extension. Already 23 states let 17- year-olds vote in certain circumstances.

Democratic legislators have tried to do this six times before; this is the first to make the ballot.

This wouldnt be a California election without at least a few wildy contentious ballot measures about housing and property taxes.

Prop. 15: Split roll

Who put it there: Citizens. Campaign largely funded by the California Teachers Association, SEIU California and the Chan Zuckerberg Initiative.

Type: Constitutional amendment

What it would do:Tax some commercial property based on its market value, rather than the price at which it was purchased. This would raise property taxes on many large businesses across the state, increasing funding for schools and local government.

In 1978, California voters passed Proposition 13, placing a cap on property taxes, kicking off a nationwide anti-tax revolt and placing city and county budgets in a generation-spanning straitjacket.

By tying a landlords property tax payments to the original purchase price, Prop. 13 has been thegift that keeps on givingto property owners, particularly those lucky enough to have bought cheap real estate decades ago. Theres been bipartisan reluctance among lawmakers to touch it ever since, lest they incur the wrath of irate homeowners.

This initiative attempts to divide and conquer that political problem by repealing the property tax protections only for commercial landlords with more than $3 million in holdings. If this measure passes, those landowners would have to make tax payments based on the current value of their properties a tax hike for most resulting in anestimated$6.5 to $11.5 billion more for cities, counties and school districts.

Prop. 19: Property tax breaks and closing the Lebowski loophole

Who put it there: The Legislature, via abillby San Mateo Democrat Assemblymember Kevin Mullin, but sponsored by the California Realtors.

Type: Constitutional amendment

What it would do: Allow homeowners who are over 55, disabled or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a state fire response fund.

Weve seen this one before half of it, anyway. In 2018, the California Association of Realtors put ameasure on the ballotallowing older or disabled homeowners to keep a portion of their Prop. 13 tax break. The Realtors argued that the current property tax rules disincentivize longtime homeowners from moving, trapping empty-nesters in houses that are too big for them and locking out new families. But because the measure would cost schools, counties and cities, it was opposed by organized labor and local government groups and failed by 20 points.

The Realtors tried again this year, but with an added fiscal sweetener. Under this proposal, anyone who inherits a home from their parents or grandparents would only be allowed to keep the low property taxes if they use the home as their primary residence and only on the first $1 million between the homes original purchase price and its market value. Inspiration for that caveat may have come from theLos Angeles Times, which tracked down a number of California scions, including The Big Lebowski star Jeff Bridges, who are still paying 1970-era property tax levels on their rental properties.

And then there was a last-minute wrinkle. In the final weeks of June, the Realtors sprang a deal: designating that most of the funding generated by the measure would go to fighting wildfires. That won the support of the influential California Professional Firefighters union. It also means the measure will be funding a public need that might be on many voters minds come November.

That bargain was struck after the Realtors had submitted their signatures, so with the help of Assemblyman Mullin, they passed it through the Legislature, pulling their original proposal just before the deadline.

Prop. 21: Rent Control (Again)

Who put it on the ballot: Signatures, collected via an effort mostly funded by the AIDS Healthcare Foundation.

Type: Statute

What it would do: Allow cities to introduce new rent control laws, or expand existing ones.

Despite a 20-percentage point, 56-out-of-58 county defeat in 2018, a statewide rent control measure is back on the ballot.

Polling from that election seasonsuggestedthat California voters generally liked rent control as a concept, but worried about the specifics of the proposal. Accordingly, this new initiative makes a few tweaks.

Under this one, cities would be allowed to apply new rent control ordinances only to homes that are at least 15 years old. And it exempts single-family homes owned by landlords with no more than two properties.

Just like last time, the measure is being pushed by the Los Angeles-based AIDS Healthcare Foundation and its pugnacious presidentMichael Weinstein. State lawmakers by passing a law last year that set a7% ceilingon how much landlords can raise rents each year had hoped to ward off another attempt by Weinstein and company. They had no such luck.

California, the home of three-strikes sentencing, has spent the last decade rethinking its approach to criminal justice. Two measures on the November ballot, channeling the spirit of the 90s, are pushing to reverse that reversal.

Prop. 25: Ditch or keep cash bail

Who put it there: Signatures, via a campaign largely funded by the bail bond industry.

Type: Referendum

What it would do: Ask voters to either approve or strike down a state law that banished money bail from the state criminal justice system.

In 2018, acting on the advice of state Supreme Court Chief Justice Tani Cantil-Sakauye, legislators passed a billending cash bail in California. Rather than letting people pay their way out of jail while they await trial, the law gives judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Moving quickly, the bail bond industry mounted a campaign to put the question on the ballot as a referendum. Voters will vote either Yes to keep the state law and end cash bail for good, making California the first state to do so, or No to keep the bail system.

Prop. 20: Rolling back Brown-era leniency

Who put it there: Signatures, via a campaign largely funded by law enforcement agencies.

Type: Constitutional amendment

What it would do: Allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole three times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Gov. Jerry Brown was famously allergic to talk of his legacy while in office. But if the former governor has one, it might be the effort he spent in his final two terms as governor supporting efforts to reverse the tough on crime policies he helped introduce during his first two terms in the 1970s and 80s.

In 2011, California legislators reduced punishments for parole violators. In 2014, voters passed Proposition 47, recategorizing some non-violent crimes as misdemeanors. In 2016, voters passed Proposition 57, giving inmates convicted of certain non-violent offenses a shot at early release.

This ballot measure would partially undo each of those.

Usually standoffs between employees and their bosses take place behind closed doors. In California, you often find them on the ballot.

Prop. 22: Self-employment for ride-hail and other app-drivers

Who put it there: Signatures, via a campaign mostly funded by Lyft, Uber and Doordash

Type: Statute

What it would do: Turn app-based drivers into independent contractors, exempting companies such as Lyft and Uber from standard wage and hour restrictions. It would also guarantee these drivers an earnings floor, a stipend to purchase health insurance and other minimum benefits.

Unless you happen to be ananti-vaccine protestor, the most controversial law of the 2019 legislative session wasAssembly Bill 5. On its face, the law simply codified a state Supreme Court ruling, making it much harder for companies to treat their workers as independent contractors, rather than full-fledged employees. In practice, it upended the business models of Uber, Lyft, Doordash, Postmates and Instacart, all of which rely on an army of phone-toting gig-workers to provide their various services.

In the months since, all attempts at legislative compromise have fizzled, Californias Attorney General hassued Uber and Lyftfor violating the new law and California regulatorsdeclaredtheir drivers to be employees.

As a last-ditch effort, the various companies implicated have poured $110 million and counting to push a ballot measure that would simply exclude their drivers from the law. And throwing a bone to critics who say their drivers are mistreated, the measure also imposes some worker benefits and protections.

Prop. 23: Regulating dialysis clinics

Who put it there: Signatures, via an effort funded entirely by the Service Employees International Union-United Healthcare Workers West

Type: Statute

What it would do: Require dialysis clinics to have at least one physician on site at all times and to report patient infection data to California health officials.

DaVita Kidney Care and Fresenius Medical Care own the majority of the for-profit dialysis clinics in the state. For years, the Service Employees International Union-United Healthcare Workers union has been at war with them.

After unsuccessful efforts to unionize clinic staff, the union sponsored legislation to cap reimbursement rates to clinics and floated an array of possible ballot measures to boost their staff spending and cut their profits. In 2018, the union finally got one on the ballot:Prop 8, which would have set a cap on clinic profit margins.

The measure was soundly defeated, but only after the two companies spent over $111 million, making it the most expensive ballot campaign ever. This one isnt likely to be much cheaper.

Two measures on this years ballot aim to bolster laws and programs already on the books. Both campaigns are led by Bay Area real estate developers with a penchant for ballot box policymaking.

Prop. 24: Stronger consumer privacy laws (again)

Who put it there: Signatures, via a campaign funded entirely by Alastair and Celine Mactaggart.

Type: Statute

What it would do: Strengthen Californias already strongest-in-the-nation consumer privacy law and establish a California Privacy Protection Agency

In 2018, California lawmakers passed theCalifornia Consumer Privacy Act, giving consumers the right to find out what data companies are collecting about them, to opt out of having it collected and to have that data scrubbed. It was and remains the only law like it in the county. It was also acompromise. San Francisco real estate developer Alastair MacTaggart had been pushing for an even stricter ballot measure, but the Legislature stepped in, brokering a deal between MacTaggart and the tech industry.

Now MacTaggart is back. Along with setting up a state agency tasked with enforcing state privacy law, the measure would beef up financial penalties for violators and allow consumers to demand that personal information not be shared at all, rather than simply not sold.

Prop. 14: Borrowing for stem cell research

Who put it there: Signatures via an effort mostly funded by Robert Klein, JDRF International and Open Philanthropy

Type: Bond

What it would do: Borrow $5.5 billion to fund stem cell research

In 2004, voters passed Proposition 71 to create the California Institute for Regenerative Medicine. The institute exists to channel state money toward stem cell research. Prop 71 also let the state borrow $3 billion to do that.

That pot of cash is now almost empty. Robert Klein, a Silicon Valley real estate developer who led the Prop. 71 effort and became the institutes first board chair, is leading the campaign for more.

CalMattersis a nonprofit, nonpartisan media venture explaining California policies and politics.

Originally posted here:
A Preview of the 12 Propositions on Californias November Ballot - Times of San Diego

COVID-19 Impact: Primary Cell Culture Market | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by…

Overview Of Primary Cell Culture Industry 2020-2026:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Primary Cell Culture Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Primary Cell Culture Market competition by top manufacturers as follow: , ATCC, Cell Biologics, CellSystems GmbH, Corning, Creative Bioarray, FUJIFILM Irvine Scientific, GE Healthcare, Irvine Scientific, Lonza, MatTek Ltd, Merck, Promocell GmbH, Themo Scientific

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/9633

The global Primary Cell Culture market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Explant Method Enzymatic Disaggregation Mechanical Separation Other

Market Segment by Applications, covers: Tissue Culture & Tissue Engineering Vaccine Production Gene Therapy and Regenerative Medicine Toxicity Testing and Drug Screening Cancer Research Prenatal Diagnosis Stem Cell Therapy Other

Market segment by Regions/Countries, this report covers North America Europe China Rest of Asia Pacific Central & South America Middle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/9633

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Primary-Cell-Culture-Market-9633

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post:
COVID-19 Impact: Primary Cell Culture Market | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by...

Trending News: Covid-19 Impact On Stem Cell Therapy Market Growth Prospects Analysis And Future Strategic Planning By 2025 | Osiris Therapeutics,…

Stem Cell Therapy Market 2020: LatestAnalysis

Chicago, United States The Stem Cell Therapy market report [5 Years Forecast 2020-2025] focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. Providing info like market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Stem Cell Therapy, with sales, revenue and global market share of Stem Cell Therapy are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Stem Cell Therapy market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The Global Stem Cell Therapy Market report briefs on the existing competitors and major market trends, covering comprehensive analysis of both growth factors and restrains those can positively or negatively impact the industry outlook during the forecast period. It entails all details about the key factors that are expected to drive the Global Stem Cell Therapy market growth during the forecast time-frame.Market data and analytics showcased in the report are a product of extensive research done on root level and so the resultant information serves as a guideline for new players willing to enter the market. The data comes from several trustworthy sources considering the degree of accuracy and reliability.

>>>>>Get a Sample PDF Copy (including full TOC, Tables, and Figures) of Stem Cell Therapy Market Report @

>>>>>>This Report Covers Leading Companies Associated in Worldwide Stem Cell Therapy Market: : Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCRPharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

Our exploration specialists acutely ascertain the significant aspects of the global Stem Cell Therapy market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Stem Cell Therapy market situation. In this Stem Cell Therapy report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Stem Cell Therapy report comprises of primary and secondary data which is exemplified in the form of pie outlines, Stem Cell Therapy tables, analytical figures, and reference diagrams. The Stem Cell Therapy report is presented in an efficient way that involves basic dialect, basic Stem Cell Therapy outline, agreements, and certain facts as per solace and comprehension.

Global Stem Cell Therapy Market by Type: Autologous Allogeneic

Global Stem Cell Therapy Market by Application: Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Market split by Sales Channel, can be divided into: Direct Channel Distribution Channel

Market segment by Region/Country including: North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Spain etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) South America Brazil, Argentina, Colombia and Chile etc.) Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

If you have any special requirement, please let us know and we can provide you the report as your requirement.

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

The global Stem Cell Therapy market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2019 and 2029.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 210 countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect this industry in 2020.

This report analyses the impact of COVID-19 on this industry. COVID-19 can affect the global market in 3 ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on enterprises and financial markets.

This report provides detailed historical analysis of global market for Stem Cell Therapy from 2014-2019, and provides extensive market forecasts from 2020-2029 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Stem Cell Therapy market.

Leading players of Stem Cell Therapy including: Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCRPharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

Market split by Type, can be divided into: Autologous Allogeneic

Market split by Application, can be divided into: Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Market split by Sales Channel, can be divided into: Direct Channel Distribution Channel

Market segment by Region/Country including: North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Spain etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) South America Brazil, Argentina, Colombia and Chile etc.) Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

If you have any special requirement, please let us know and we can provide you the report as your requirement.

Reasons to Purchase this Report:

To understand the impact of end-user applications on the market Analyzing various perspectives of the market To understand the dominating type in the market Countries expected to witness the fastest growth during the forecast period Identify the latest developments, market shares, and strategies employed by the major market players

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

Strategic Points Covered in TOC: Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Stem Cell Therapy market.

Chapter 2:Evaluating the leading manufacturers of the global Stem Cell Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3:Displaying the competitive nature among key manufacturers, with market share, revenue, and sales. Chapter 4:Presenting global Stem Cell Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Get Full Customize report @ https://www.reporthive.com/request_customization/2359708

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com Email: [emailprotected] Phone:+1 312-604-7084

More here:
Trending News: Covid-19 Impact On Stem Cell Therapy Market Growth Prospects Analysis And Future Strategic Planning By 2025 | Osiris Therapeutics,...

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data – Yahoo Finance

Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and confidential information to third parties who have no ownership or custodial right to it.

Hemostemix engaged the services of Accudata to conduct, pursuant to a Consulting Agreement executed in August 2019, a statistical analysis of the clinical trial midpoint data. All clinical trial data and, in particular, the clinical trial midpoint analysis and supporting data are, and always have been, the property of Hemostemix. Hemostemix has an absolute ownership right over that data and an absolute right to recover the data upon demand. Despite repeated requests, Accudata has failed and refused to return the midpoint data to Hemostemix.

Hemostemix also recently learned that, while refusing to return the clinical trial midpoint data to Hemostemix, Accudata produced a copy of the midpoint data and report to an agent of the former Contract Research Organization ("CRO"), Aspire Health Science, LLC ("Aspire") and Aspire is now blocking Hemostemix from obtaining the return of its clinical trial data. Neither Aspire nor any of its agents or representatives have any ownership or any other right to have, maintain, or withhold such data, or to hold such data to the exclusion of Hemostemix. Hemostemix seeks the Court's immediate intervention to enjoin Accudata's continued breaches of the parties' agreement.

Hemostemix filed in the United States District Court for the District of Delaware.

On June 25, 2020 counsel for Hemostemix presented oral argument to the 9th Circuit Court in and for Orange County, Florida on its motion to dismiss Aspire's lawsuit on grounds that, among other things, Hemostemix's threshold challenge that it is not subject to jurisdiction in Florida. A decision on Hemostemix's motion is pending. In the meantime, the presiding judge has stayed a hearing on Aspire's Motion for a Speedy Hearing previously set for June 29, 2020 pending a decision on Hemostemix's motion to dismiss.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-Founder TSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information regarding: the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any required or desired financings of Hemostemix, including TSX Venture Exchange acceptance and any third party consents; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Story continues

Read the original:
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data - Yahoo Finance

Trending: Cell Therapy Market Brief Analysis and Application, Growth by 2026 – 3rd Watch News

LOS ANGELES, United States: QY Research has recently published a report, titled Global Cell Therapy Market Professional Survey Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Cell Therapy market include: Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type, , , Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1916335/global-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cell Therapy Market Segment By Type:

Stem Cell Non-Stem Cell

Global Cell Therapy Market Segment By Application:

Market Analysis and Insights: Global Cell Therapy Market The global Cell Therapy market was valued at US$ 77485 million in 2019 and it is expected to reach US$ 362235 million by the end of 2026, growing at a CAGR of 27.18% during 2020-2026. Global Cell Therapy Scope and Market Size Cell Therapy market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Cell Therapy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyzes the impact of Coronavirus COVID-19 on the Cell Therapy industry. By Company Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type

Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cell Therapy market.

Key companies operating in the global Cell Therapy market include Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type, , , Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1916335/global-cell-therapy-market

TOC

1 REPORT OVERVIEW1 1.1 Study Scope1 1.2 Key Market Segments1 1.3 Players Covered: Ranking by Cell Therapy Revenue2 1.4 Market Analysis by Type2 1.4.1 Global Cell Therapy Market Size Growth Rate by Type: 2020 VS 20262 1.4.2 Stem Cell4 1.4.3 Non-Stem Cell5 1.5 Market by Application6 1.5.1 Global Cell Therapy Market Share by Application: 2020 VS 20266 1.5.2 Hospital8 1.5.3 Clinic8 1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth9 1.6.1 How the Covid-19 is Affecting the Cell Therapy Industry9 1.6.2 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections11 1.6.3 Covid-19 Impact: Commodity Prices Indices20 1.6.4 Covid-19 Impact: Global Major Government Policy25 1.6.5 Proposal for Cell Therapy Players to Combat Covid-19 Impact29 1.7 Study Objectives31 1.8 Years Considered31 2 GLOBAL GROWTH TRENDS32 2.1 Global Cell Therapy Market Perspective (2015-2026)32 2.2 Cell Therapy Growth Trends by Regions33 2.2.1 Cell Therapy Market Size by Regions: 2015 VS 2020 VS 202633 2.2.2 Cell Therapy Historic Market Size by Regions (2015-2020)35 2.2.3 Cell Therapy Forecasted Market Size by Regions (2021-2026)35 2.3 Industry Trends and Growth Strategy37 2.3.1 Market Top Trends37 2.3.2 Market Drivers37 2.3.3 Market Challenges38 2.3.4 Porter Five Forces Analysis39 2.3.5 Advantages of Allogeneic Over Autologous Cell Therapy Products40 3 COMPETITION LANDSCAPE BY KEY PLAYERS42 3.1 Global Top Cell Therapy Players by Market Size42 3.1.1 Global Top Cell Therapy Players by Revenue (2019-2020)42 3.1.2 Global Cell Therapy Revenue Market Share by Players (2019-2020)43 3.1.3 Global Cell Therapy by Company Type (Tier 1, Tier 2 and Tier 3)44 3.2 Global Cell Therapy Market Concentration Ratio44 3.2.1 Global Cell Therapy Market Concentration Ratio (CR5)44 3.2.2 Global Top 5 Companies by Cell Therapy Revenue in 201945 3.3 Cell Therapy Key Players Head office and Area Served45 3.4 Key Players Cell Therapy Product Solution and Service46 3.5 Date of Enter into Cell Therapy Market46 3.6 Mergers & Acquisitions, Expansion Plans47 4 CELL THERAPY BREAKDOWN DATA BY TYPE (2015-2026)51 4.1 Global Cell Therapy Historic Market Size by Type (2015-2020)51 4.2 Global Cell Therapy Forecasted Market Size by Type (2021-2026)52 5 CELL THERAPY BREAKDOWN DATA BY APPLICATION (2015-2026)54 5.1 Global Cell Therapy Historic Market Size by Application (2015-2020)54 5.2 Global Cell Therapy Forecasted Market Size by Application (2021-2026)55 6 NORTH AMERICA57 6.1 North America Cell Therapy Market Size (2015-2026)57 6.2 Cell Therapy Key Players in North America (2019-2020)57 6.3 North America Cell Therapy Market Size by Type (2015-2020)58 6.4 North America Cell Therapy Market Size by Application (2015-2020)59 7 EUROPE60 7.1 Europe Cell Therapy Market Size (2015-2026)60 7.2 Cell Therapy Key Players in Europe (2019-2020)60 7.3 Europe Cell Therapy Market Size by Type (2015-2020)61 7.4 Europe Cell Therapy Market Size by Application (2015-2020)61 8 JAPAN63 8.1 Japan Cell Therapy Market Size (2015-2026)63 8.2 Cell Therapy Key Players in Japan (2019-2020)63 8.3 Japan Cell Therapy Market Size by Type (2015-2020)64 8.4 Japan Cell Therapy Market Size by Application (2015-2020)64 9 CHINA66 9.1 China Cell Therapy Market Size (2015-2026)66 9.2 Cell Therapy Key Players in China (2019-2020)66 9.3 China Cell Therapy Market Size by Type (2015-2020)67 9.4 China Cell Therapy Market Size by Application (2015-2020)67 10 SOUTHEAST ASIA69 10.1 Southeast Asia Cell Therapy Market Size (2015-2026)69 10.2 Cell Therapy Key Players in Southeast Asia (2019-2020)69 10.3 Southeast Asia Cell Therapy Market Size by Type (2015-2020)70 10.4 Southeast Asia Cell Therapy Market Size by Application (2015-2020)70 11 INDIA72 11.1 India Cell Therapy Market Size (2015-2026)72 11.2 Cell Therapy Key Players in India (2019-2020)72 11.3 India Cell Therapy Market Size by Type (2015-2020)73 11.4 India Cell Therapy Market Size by Application (2015-2020)73 12 KEY PLAYERS PROFILES75 12.1 Gilead Sciences75 12.1.1 Gilead Sciences Company Details75 12.1.2 Gilead Sciences Cell Therapy Introduction76 12.1.3 Gilead Sciences Revenue in Cell Therapy Business (2019-2020)76 12.2 Novartis77 12.2.1 Novartis Company Details77 12.2.2 Novartis Cell Therapy Introduction78 12.2.3 Novartis Revenue in Cell Therapy Business (2019-2020)79 12.3 Osiris79 12.3.1 Osiris Company Details79 12.3.2 Osiris Cell Therapy Introduction80 12.3.3 Osiris Revenue in Cell Therapy Business (2019-2020)81 12.4 Vericel Corporation81 12.4.1 Vericel Corporation Company Details81 12.4.2 Vericel Corporation Cell Therapy Introduction82 12.4.3 Vericel Corporation Revenue in Cell Therapy Business (2019-2020)83 12.5 Vcanbio83 12.5.1 Vcanbio Company Details83 12.5.2 Vcanbio Cell Therapy Introduction84 12.5.3 Vcanbio Revenue in Cell Therapy Business (2019-2020)84 12.6 Fujifilm Cellular Dynamics85 12.6.1 Fujifilm Cellular Dynamics Company Details85 12.6.2 Fujifilm Cellular Dynamics Cell Therapy Introduction86 12.6.3 Fujifilm Cellular Dynamics Revenue in Cell Therapy Business (2019-2020)86 12.7 JCR Pharmaceuticals87 12.7.1 JCR Pharmaceuticals Company Details87 12.7.2 JCR Pharmaceuticals Cell Therapy Introduction88 12.7.3 JCR Pharmaceuticals Revenue in Cell Therapy Business (2019-2020)89 12.8 Beike Biotechnology89 12.8.1 Beike Biotechnology Company Details89 12.8.2 Beike Biotechnology Cell Therapy Introduction90 12.8.3 Beike Biotechnology Revenue in Cell Therapy Business (2019-2020)90 12.9 Golden Meditech91 12.9.1 Golden Meditech Company Details91 12.9.2 Golden Meditech Cell Therapy Introduction91 12.9.3 Golden Meditech Revenue in Cell Therapy Business (2019-2020)92 12.10 Guanhao Biotech92 12.10.1 Guanhao Biotech Company Details92 12.10.2 Guanhao Biotech Cell Therapy Introduction93 12.10.3 Guanhao Biotech Revenue in Cell Therapy Business (2019-2020)94 13 ANALYSTS VIEWPOINTS/CONCLUSIONS95 14 APPENDIX96 14.1 Research Methodology96 14.1.1 Methodology/Research Approach96 14.1.2 Data Source99 14.2 Disclaimer102 14.3 Author Details102

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the rest here:
Trending: Cell Therapy Market Brief Analysis and Application, Growth by 2026 - 3rd Watch News

Transplant patient turns to art to raise money for charity which saved her life – Bishop’s Stortford Independent

A young Bishop's Stortford woman who suffers from a rare immune disorder has completed a challenge to paint every day for a month to raise money for the Anthony Nolan charity.

Michelle Peppiatt, 30, received a stem cell transplant last year after the organisation found her a matching donor and is now recovering at her home in Wallace Court where she has been shielding since before the coronavirus outbreak.

Art has proved a great outlet for Michelle in keeping her anxiety at bay and at the completion of her challenge yesterday (June 30) she had raised more than 700. "At the beginning of the month I decided to fundraise for Anthony Nolan, who save the lives of thousands with blood disorders. But I started to wonder how they were getting by during Covid-19 and it suddenly hit me that it could have been me and I might not have had my transplant so I decided to fundraise by taking art every day for the duration of June.

"Post transplant I really struggled to find things I was capable of doing due to the effects of the treatment and just stumbled across art and thought I would give it a go. I fell in love with it - it's been a great outlet for me."

Michelle's condition is known as Haemophagocytic lymphohistiocytosis (HLH), a rare immune disorder where the body reacts inappropriately to a trigger, usually an infection. There are two forms of HLH - primary which is a genetic type and secondary which is caused by a malignant blood cancer or acute infection/virus.

Michelle was diagnosed with lymphoma first and then the HLH was discovered. She said: "I had the treatment that is suggested for HLH which is eight weeks of chemotherapy and immune therapy. I relapsed three times after several rounds of chemotherapy immune therapy and biological therapies - my only chance at surviving was a stem cell transplant.

"The HLH had affected all my organs and muscles. But my medical team turned to Anthony Nolan to help. Anthony Nolan search every stem cell donor register in the world to find some one who is a perfect genetic match. I received my stem cell transplant in January 2019. I have long term effects of treatment and art helps me manage anxiety, pain, fatigue and isolation.

"I spent a number of weeks and months in isolation during treatment, due to infections and after the transplant. I'm adjusted to being sheilded and have learnt to keep myself occupied. I have had to find ways to manage my anxiety and general mental health."

Michelle describes her work as fluid art using acrylics and each day has picked a subject matter out of a pot. "Today was oceans and I made art based on the colours of the ocean. I've been painting every day, usually three paintings a day, and sell them via my Facebook page, but now we're at the end I'm looking to expand because they are still selling and I hope to reach more people," she said.

"And now that I have created a space for continuing after this I possibly will set it up as a business. "

She said the experience of lockdown "wasn't too bad as I have spent the last three and a half years in isolation" and discovering art had been a great help. "It has been incredibly therapeutic for me. It has no boundaries, it's very freeing."

On her Facebook posts, Michelle says: "At the start of this I did begin to wonder what I'd let myself in for. When I look at my paintings I've accomplished I feel something I haven't felt in a long time. Peace. A moment of mindfullness and connection!"

Michelle's remaining paintings will still be on sale until August 1. Visit @chelepep/freedomart on Facebook or her instagram page @chellepep for more details.

The rest is here:
Transplant patient turns to art to raise money for charity which saved her life - Bishop's Stortford Independent